(Total Views: 304)
Posted On: 01/20/2022 7:45:27 AM
Post# of 102752
$QNTA News : Medolife Rx Submits Final Clinical Trial Data for Escozine Approval as a COVID-19 Treatment in The Dominican Republic
BURBANK, Calif., Jan. 19, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Medolife Rx, Inc. ("Medolife"
, a global integrated biopharmaceutical company with R&D, manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc. (OTCQB: QNTA), announced today that the Company submitted the final clinical trial data to the Dominican Republic (“DR”) Ministry of Health (“MoH”) for approval of the Company’s product, Escozine, as a COVID-19 treatment. The product, which is registered as an alternative oncological medicine in the DR, has shown to be effective against variations of the SARS-CoV-2 virus.
https://finance.yahoo.com/news/medolife-rx-su...00052.html
BURBANK, Calif., Jan. 19, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Medolife Rx, Inc. ("Medolife"
, a global integrated biopharmaceutical company with R&D, manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc. (OTCQB: QNTA), announced today that the Company submitted the final clinical trial data to the Dominican Republic (“DR”) Ministry of Health (“MoH”) for approval of the Company’s product, Escozine, as a COVID-19 treatment. The product, which is registered as an alternative oncological medicine in the DR, has shown to be effective against variations of the SARS-CoV-2 virus. https://finance.yahoo.com/news/medolife-rx-su...00052.html
(0)
(0)
